<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016753</url>
  </required_header>
  <id_info>
    <org_study_id>IM026-021</org_study_id>
    <nct_id>NCT04016753</nct_id>
  </id_info>
  <brief_title>A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants</brief_title>
  <official_title>The Effect of BMS-986256 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparative study of BMS-986256 with a combined oral contraceptive in healthy female&#xD;
      participants to determine the effectiveness when taken together&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma Concentration (Cmax) of Norethindrone (NET)</measure>
    <time_frame>Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval AUC(TAU) of NET</measure>
    <time_frame>Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma Concentration (Cmax) of Ethinyl Estradiol (EE)</measure>
    <time_frame>Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve over the dosing interval AUC(TAU)of (EE)</measure>
    <time_frame>Day 21 of cycle 1 and cycle 2 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology clinical lab assessment of blood</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology clinical lab assessments of blood</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis clinical lab assessment</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs of blood pressure</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs of body temperature</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs of respiratory rate</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with abnormal physical examination findings</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986256</intervention_name>
    <description>30 mg(6ml)</description>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loestrin</intervention_name>
    <description>1.5 mg Norethindrone and 30ug ethinyl estradiol</description>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be a non- smoking genetically female, who has normal renal function,&#xD;
             willing to use Loestrin, and of childbearing Potential with intact ovarian function.&#xD;
&#xD;
          -  Participants must be healthy, defined as having no clinically significant active or&#xD;
             ongoing medical condition Weighing less than or equal to 50 kg and a body mass index&#xD;
             between 18.0 and 32.0kg inclusive at screening.&#xD;
&#xD;
          -  Participant must have a negative QuantiFeron- TB Gold test at screening and have a&#xD;
             normal pap smear result within 3 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are involuntarily incarcerated, have a significant Chronic medical&#xD;
             illness or a history of relevant drug allergy to immunologic or related compounds.&#xD;
&#xD;
          -  Any serious bacterial, fungal, or viral infection within 3 months or a history of&#xD;
             recurrent or chronic infection or Risk for TB.&#xD;
&#xD;
          -  A history of any medical condition specifically related to the use of hormonal&#xD;
             contraceptives as well as an average intake of more than 21 units of alcohol per week.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

